SmartCube integrates behavioral neurobiology, robotics and computer vision to process and analyze large temporal and vector-based datasets. This platform uses proprietary bioinformatics and probabilistic causal inference algorithms to explore compounds’ potential to treat psychiatric disorders. [Image courtesy of PsychoGenics]
In an era of rapid AI progress, the quest to pioneer the first AI-developed drug candidates has led to an increasing number of these drug candidates entering clinical trials. One contender is ulotaront, an antipsychotic drug, that fared well in a phase 3 schizophrenia study published in NEJM in 2020. The trace amine-associated receptor 1 agonist has entered phase 2/3 studies to test its potential in generalized anxiety disorder and as an adjunctive therapy for major depressive disorder treatment.
“Not only is this the first drug discovered using machine learning that’s th…